MONTREAL, April 20 /PRNewswire/ -- Chronogen Inc. (http://www.chronogen-inc.com/), a drug discovery company developing human therapeutics to treat age-dependent diseases, announced today the appointment of Mr. Kees Been, to the company's Board of Directors.
Mr. Been is Chief Executive Officer of Bionaut Pharmaceuticals, a pioneering company using a highly predictive, cell-based assay platform, for small molecule drug discovery and lead optimization. He most recently served as Senior Vice President of Biogen's Oncology Business Unit, after having been responsible for all of Biogen's activities in business development, mergers and acquisitions, corporate strategy and portfolio management for a 2-year period. Prior to this, he held various executive positions related to international growth strategy with Monsanto Life Sciences and was responsible for building the pharmaceuticals practice of Gemini consulting until 1995. Mr. Been holds an MBA from INSEAD in France and a Masters of Biotechnology from the University of Agriculture, The Netherlands.
"Mr. Been brings proven track record and expertise in business development, portfolio management and corporate strategy from life science industry, enabling us to benefit from his experience to advance our company quickly" said Iraj Beheshti, President and CEO of Chronogen. "We are delighted to benefit from Mr. Been's world-class management experience".
Chronogen Inc., a privately-held drug discovery company, is a leader in
the identification of targets that control the degenerative processes of
aging. Based on this innovative approach, the company is developing novel
products to control lipid and oxidative stress levels, which are
established disease mechanisms in cardiovascular disorders. The control
of aging in whole model organisms has provided very valuable assets for a
drug discovery technology that will lead to novel and efficacious drugs
in significant markets including atherosclerosis, vascular complications
of diabetes, and ischemia/reperfusion injuries. Chronogen is
headquartered in Montreal, Canada. Further information can be found at
CONTACT: Iraj Beheshti, President & CEO, (514)-521-9595,ext. 202, email@example.com; Marie-Lise Gauthier, Vice Presidentof Finance, (514) 21-9595, ext.206, firstname.lastname@example.org